Keywords: first, phase, iii, data, gw, agenerase, glaxo
First Phase III Data With GW's Agenerase
Article | 01 October 1998
The first Phase III data with Glaxo Wellcome's investigational HIVprotease inhibitor Agenerase (amprenavir; formerly 141W94), originally developed by Vertex Pharmaceuticals, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
